Zantac Linked To Esophageal Cancer

Many cancer cases have been brought against Zantac (ranitidine) since filing a recall request in September 2019. Companies that perform routine tests for the popular acid/antacid drug have found that it contains dangerous levels of the well-known carcinogen NDMA or N-nitrosodimethylamine. This resulted in a widespread recall by the company that made the drug, as well as the removal of these products from pharmaceutical shelves across the country.

Zantac users with cancer are suing the acidity medication litigation on the drug's manufacturer on several counts, including strict liability, negligence, design flaw, and, failure to warn. In this case, it was stated that the drug company was responsible for testing the drug. Products and are required to report the actual "nature, quality, and consistency" of the drug.

Zantac (Ranitidine) Litigation - RLB

Image Source: Google

What additional cancers are associated with using Zantac?

Zantac and similar drugs have been used and marketed as safe since ranitidine was introduced in the 1980s. Many people with heartburn, acid reflux, and other similar symptoms use medication for years or even decades to manage their symptoms.

Zantac may be associated with various types of cancer because the formation of NDMA can occur in various parts of the body after taking Zantac (ranitidine). It is unfortunate that you have developed at least one of the following cancers from regular and prolonged use of Zantac or similar heartburn medications.

  • Bladder cancer
  • Stomach cancer
  • Heart cancer
  • Colon cancer
  • Kidney cancer
  • Leukemia
  • Multiple myeloma
  • Non-Hodgkin's Lymphoma
  • Pancreatic cancer
  • Prostate cancer
  • Small bowel cancer